The Rare Cancer Network: achievements from 1993 to 2012

Area of Science:

• Oncology
• Rare Diseases
• Clinical Research

Background:

• The Rare Cancer Network (RCN) was established in 1993 to address the research gap in rare tumors.
• Prospective studies are often not feasible for rare tumor types due to low incidence.
• The RCN has initiated over 55 studies, with 30 completed or in progress.

Purpose of the Study:

• To provide an overview of the 30 studies conducted by the RCN.
• To categorize these studies by disease site.
• To highlight the diversity of rare pathologies investigated.

Main Methods:

• Review and organization of 30 completed or ongoing RCN studies.
• Categorization of studies by anatomical site (e.g., breast, prostate, head and neck, CNS).
• Inclusion of studies on a wide range of rare tumor types.

Main Results:

• Five breast pathology studies cover sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and DCIS in young women.
• Three prostate cancer studies address small cell carcinoma and adenocarcinoma in different age groups.
• Six head and neck studies include lymphomas, melanoma, nasopharyngeal carcinoma, neuroblastoma, and MALT lymphoma.
• Four CNS studies focus on glioblastoma, meningioma, spinal lymphoma, and ependymoma.
• Additional studies cover rare tumors like uterine leiomyosarcoma and giant cell bone tumors.

Conclusions:

• RCN studies encompass a broad spectrum of rare pathologies previously limited to case reports or small series.
• Continued growth and collaboration within the RCN will enhance the analysis of rare tumors.
• Improved understanding of rare tumor behavior will guide future research and potentially improve patient outcomes.